Erlotinib antagonizes ABC transporters in acute myeloid leukemia

Cell Cycle

Volumn 11, Issue 21, 2012, Pages 4079-4092

  Lainey, Elodie ^a,b,c   Seb́ert, Marie ^d   Thépot, Sylvain ^d   Scoazec, Marie ^a,b   Bouteloup, Cyrielle ^a,b   Leroy, Carole ^a,b   De Botton, Stéphane ^b   Galluzzi, Lorenzo ^b,e   Fenaux, Pierre ^a,d   Kroemer, Guido ^a,e,f,g  

^a Institut Gustave Roussy   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d AVICENNE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Calcein; Cytarabine; KO 143; MK 571; Verapamil; VP16

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; 2 MORPHOLINO 8 PHENYLCHROMONE; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; CALCEIN; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; RAPAMYCIN; THREONINE; TYROSINE; VERAPAMIL; VERLUKAST;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG TRANSPORT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84869477687     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22382     Document Type: Article

References (56)

1. Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance- associated protein, MRP. Eur J Cancer 1996; 32A:945-57; PMID:8763335; http://dx.doi.org/10.1016/0959-8049(96)00046-9.
2. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106:1154-63; PMID:15870183; http://dx.doi.org/10.1182/ blood-2005-01-0178.
3. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 2007; 86:329-37; PMID:17340137; http://dx.doi.org/10. 1007/s00277-007-0269-7.
4. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001; 98:1166-73; PMID:11493466; http://dx.doi.org/10.1182/ blood.V98.4.1166.
5. Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia 2007; 21:1172-6; PMID:17429427; http://dx.doi.org/10.1038/sj.leu.2404692.
6. Pallis M, Hills R, White P, Grundy M, Russell N, Burnett A. Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial. Blood Cancer J 2011; 1:e23; PMID:22829167; http://dx.doi.org/10.1038/bcj.2011.23.
7. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89:3323-9; PMID:9129038.
8. Hirsch P, Tang R, Marzac C, Perrot JY, Fava F, Bernard C, et al. Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC. Haematologica 2012; 97:241-5; PMID:22058196; http://dx.doi.org/10. 3324/haematol.2010.034447.
9. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98:3212-20; PMID:11719356; http://dx.doi.org/10.1182/blood.V98.12.3212.
10. Shtil AA, Azare J. Redundancy of biological regulation as the basis of emergence of multidrug resistance. Int Rev Cytol 2005; 246:1-29; PMID:16164965; http://dx.doi.org/10.1016/S0074-7696(05)46001-5.
11. Settleman J. Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer. Cell Cycle 2004; 3:1496-7; PMID:15539955; http://dx.doi.org/10.4161/cc.3.12.1325.
12. Ji H, Sharpless NE, Wong KK. EGFR targeted therapy: view from biological standpoint. Cell Cycle 2006; 5:2072-6; PMID:16969107; http://dx.doi.org/10.4161/ cc.5.18.3277.
13. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 2005; 106:2841-8; PMID:15998836; http://dx.doi.org/10.1182/blood-2005-02-0488.
14. Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, et al. Erlotinib exhibits antineoplastic offtarget effects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; http://dx.doi.org/10. 1182/blood-2007-07-100362.
15. Boehrer S, Adès L, Galluzzi L, Tajeddine N, Tailler M, Gardin C, et al. Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. Biochem Pharmacol 2008; 76:1417-25; PMID:18617157; http://dx.doi.org/10.1016/j.bcp.2008.05.024.
16. Chan G, Pilichowska M. Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood 2007; 110:1079-80; PMID:17644748; http://dx.doi.org/10.1182/blood-2007-01- 069856.
17. Pitini V, Arrigo C, Altavilla G. Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol 2008; 26:3645-6; PMID:18640945; http://dx.doi.org/10.1200/JCO.2008.17.0357.
18. Komrokji RS, Lancet JE, Yu D, Santana E, Yan L, Smith PS, et al. Erlotinib for treatment of myelodysplastic syndromes: A phase II clinical study. Blood 2010; 116.
19. Lainey E, Wolfromm A, Marie N, Enot D, Scoazec M, Bouteloup C, et al. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene 2012; In press.
20. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 2005; 49:337-43; PMID:15955594; http://dx.doi.org/10.1016/j.lungcan.2005.03.035.
21. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007; 67:11012-20; PMID:18006847; http://dx.doi.org/10.1158/0008-5472.CAN-07- 2686.
22. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci 2009; 100:1701-7; PMID:19493273; http://dx.doi.org/10.1111/j.1349-7006.2009.01213.x.
23. Bailly JD, Muller C, Jaffrézou JP, Demur C, Gassar G, Bordier C, et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 1995; 9:799-807; PMID:7769842.
24. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 2002; 16:1443-7; PMID:12145683; http://dx.doi.org/10.1038/sj.leu.2402541.
25. Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 2003; 101:4589-97; PMID:12576328; http://dx.doi.org/10.1182/blood-2002-07-2311.
26. Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2005; 23:482-93; PMID:15534356; http://dx.doi.org/10.1200/ JCO.2005.06.090.
27. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009; 16:1093-107; PMID:19373242; http://dx.doi.org/10.1038/cdd.2009.44.
28. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 2007; 12:803-13; PMID:17294081; http://dx.doi.org/10.1007/ s10495-007-0720-1.
29. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10:221-37; PMID:21358741; http://dx.doi.org/10.1038/nrd3373.
30. Harbron C. A flexible unified approach to the analysis of pre-clinical combination studies. Stat Med 2010; 29:1746-56; PMID:20572122; http://dx.doi.org/10.1002/sim.3916.
31. Walter RB, Pirga JL, Cronk MR, Mayer S, Appelbaum FR, Banker DE. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood 2005; 106:3584-93; PMID:16051742; http://dx.doi.org/10.1182/blood-2005-02-0711.
32. Feller N, Broxterman HJ, Währer DC, Pinedo HM. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 1995; 368:385-8; PMID:7628644; http://dx.doi.org/10.1016/0014-5793(95)00677-2.
33. Tsimberidou AM, Paterakis G, Androutsos G, Anagnostopoulos N, Galanopoulos A, Kalmantis T, et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res 2002; 26:143-54; PMID:11755464; http://dx.doi.org/10.1016/S0145-2126(01) 00106-0.
34. Guo Y, Lübbert M, Engelhardt M. CD34- hematopoietic stem cells: current concepts and controversies. Stem Cells 2003; 21:15-20; PMID:12529547; http://dx.doi.org/10.1634/stemcells.21-1-15.
35. Koeffler HP, Billing R, Lusis AJ, Sparkes R, Golde DW. An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood 1980; 56:265-73; PMID:6967340.
36. Lan ZJ, Tang YM, Shen HQ, Qian BQ, Ning BT, Chen YH. Evaluation of the P-gp pump function on leukemic cell membrane and proper application of its reversal agents with Calcein-AM and flow cytometry. Zhonghua Er Ke Za Zhi 2007; 45:334-8; PMID:17697617.
37. Hirose M. Biology and modulation of multidrug resistance (MDR) in hematological malignancies. Int J Hematol 2002; 76(Suppl 2):206-11; PMID:12430927; http://dx.doi.org/10.1007/BF03165119.
38. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011; 10:4230-6; PMID:22107964; http://dx.doi.org/10.4161/cc.10.24.18486.
39. Blagosklonny MV. Rapamycin and quasi-programmed aging: four years later. Cell Cycle 2010; 9:1859-62; PMID:20436272; http://dx.doi.org/10.4161/ cc.9.10.11872.
40. Cozzi M, Giorgi F, Marcelli E, Pentimalli F, Forte IM, Schenone S, et al. Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition. Cell Cycle 2012; 11:1029-39; PMID:22333592; http://dx.doi.org/10.4161/ cc.11.5.19519.
41. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009; 8:1896-900; PMID:19478560; http://dx.doi.org/10. 4161/cc.8.12.8809.
42. Xu R, Spencer VA, Groesser DL, Bissell MJ. Laminin regulates PI3K basal localization and activation to sustain STAT5 activation. Cell Cycle 2010; 9:4315-22; PMID:20980837; http://dx.doi.org/10.4161/ cc.9.21.13578.
43. Lindhagen E, Eriksson A, Wickström M, Danielsson K, Grundmark B, Henriksson R, et al. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol 2008; 81:344-53; PMID:18637032.
44. Boehrer S, Galluzzi L, Lainey E, Bouteloup C, Tailler M, Harper F, et al. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle 2011; 10:3168- 75; PMID:21897118; http://dx.doi.org/10.4161/cc.10.18.16599.
45. de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 2012; 30:443-9; PMID:20963470; http://dx.doi.org/10.1007/s10637-010-9569-1.
46. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 2008; 7:2280-7; PMID:18723475; http://dx.doi.org/10.1158/1535-7163.MCT-07-2250.
47. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T; SHG AML96 Study Group. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005; 128:324-32; PMID:15667534; http://dx.doi.org/10.1111/j.1365-2141.2004.05319.x.
48. Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 2010; 596:341-58; PMID:19949931; http://dx.doi.org/10.1007/978-1-60761-416-6-15.
49. van der Holt B, Löwenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005; 106:2646-54; PMID:15994288; http://dx.doi.org/10.1182/ blood-2005-04-1395.
50. Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T, et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 2008; 8:51; PMID:18271955; http://dx.doi.org/10.1186/ 1471-2407-8-51.
51. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis 2010; 1:e10; PMID:21364612; http://dx.doi.org/10.1038/cddis.2009.8.
52. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-62; PMID:17616683; http://dx.doi.org/10.1158/0008-5472.CAN-07- 0538.
53. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70:1793-803; PMID:20145152; http://dx.doi.org/10.1158/0008-5472.CAN-09- 3112.
54. Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L, et al. The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ 2009; 16:1006-17; PMID:19325567; http://dx.doi.org/10.1038/cdd.2009.34.
55. Criollo A, Galluzzi L, Maiuri MC, Tasdemir E, Lavandero S, Kroemer G. Mitochondrial control of cell death induced by hyperosmotic stress. Apoptosis 2007; 12:3-18; PMID:17080328; http://dx.doi.org/10.1007/s10495-006-0328-x.
56. Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, et al. Prognostic impact of vitamin b6 metabolism in lung cancer. Cell Rep 2012; 2:257- 69; PMID:22854025; http://dx.doi.org/10.1016/j.celrep. 2012.06.017.